Generics win anti-pay-for-delay bill challenge

14-12-2021

Alex Baldwin

Generics win anti-pay-for-delay bill challenge

Vivi-o / Shutterstock.com

The Association for Accessible Medicines (AAM), which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.


AAM, Generics, reverse payment, California, Pay-for-delay, Ninth Circuit, Kirkland & Elis

LSIPR